Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

A Phase 2 Study Evaluating the Safety, Tolerability, and Immunogenicity of Two 3-Dose Regimens of a Clostridium difficile Vaccine in Healthy US Adults Aged 65 to 85 Years.

Kitchin N, Remich SA, Peterson J, Peng Y, Gruber WC, Jansen KU, Pride MW, Anderson AS, Knirsch C, Webber C.

Clin Infect Dis. 2019 May 24. pii: ciz153. doi: 10.1093/cid/ciz153. [Epub ahead of print]

PMID:
31125055
2.

Pneumococcal epidemiology among us adults hospitalized for community-acquired pneumonia.

Isturiz RE, Ramirez J, Self WH, Grijalva CG, Counselman FL, Volturo G, Ostrosky-Zeichner L, Peyrani P, Wunderink RG, Sherwin R, Overcash JS, Oliva SP, File T, Wiemken TL, McLaughlin JM, Pride MW, Gray S, Alexander R, Ford KD, Jiang Q, Jodar L.

Vaccine. 2019 May 31;37(25):3352-3361. doi: 10.1016/j.vaccine.2019.04.087. Epub 2019 May 6.

3.

A phase 1 randomized study assessing safety and immunogenicity of two 3-dose regimens of a Clostridium difficile vaccine in healthy older Japanese adults.

Inoue M, Yonemura T, de Solom R, Yamaji M, Aizawa M, Knirsch C, Pride MW, Jansen KU, Gruber W, Webber C.

Vaccine. 2019 May 1;37(19):2600-2607. doi: 10.1016/j.vaccine.2019.03.014. Epub 2019 Apr 5.

PMID:
30962095
4.

Evaluation of a Validated Luminex-Based Multiplex Immunoassay for Measuring Immunoglobulin G Antibodies in Serum to Pneumococcal Capsular Polysaccharides.

Tan CY, Immermann FW, Sebastian S, Pride MW, Pavliakova D, Belanger KA, Watson W, Scott DA, Sidhu M, Jansen KU, Giardina PC.

mSphere. 2018 Aug 8;3(4). pii: e00127-18. doi: 10.1128/mSphere.00127-18.

5.

Predicting the Susceptibility of Meningococcal Serogroup B Isolates to Bactericidal Antibodies Elicited by Bivalent rLP2086, a Novel Prophylactic Vaccine.

McNeil LK, Donald RGK, Gribenko A, French R, Lambert N, Harris SL, Jones TR, Li S, Zlotnick G, Vogel U, Claus H, Abad R, Vazquez JA, Borrow R, Findlow J, Taha MK, Deghmane AE, Caugant DA, Kriz P, Musilek M, Wang X, Vuong J, Mayer LW, Pride MW, Jansen KU, Anderson AS.

MBio. 2018 Mar 13;9(2). pii: e00036-18. doi: 10.1128/mBio.00036-18.

6.

Reevaluation of Positivity Cutoff Values for the Pneumococcal Urinary Antigen Detection Assay.

Pride MW, Jansen KU.

Clin Vaccine Immunol. 2017 Nov 6;24(11). pii: e00239-17. doi: 10.1128/CVI.00239-17. Print 2017 Nov. No abstract available.

7.

Neutrophil killing of Staphylococcus aureus in diabetes, obesity and metabolic syndrome: a prospective cellular surveillance study.

Scully IL, McNeil LK, Pathirana S, Singer CL, Liu Y, Mullen S, Girgenti D, Gurtman A, Pride MW, Jansen KU, Huang PL, Anderson AS.

Diabetol Metab Syndr. 2017 Oct 3;9:76. doi: 10.1186/s13098-017-0276-3. eCollection 2017.

8.

Longitudinal multiparameter single-cell analysis of macaques immunized with pneumococcal protein-conjugated or unconjugated polysaccharide vaccines reveals distinct antigen specific memory B cell repertoires.

Jia B, McNeil LK, Dupont CD, Tsioris K, Barry RM, Scully IL, Ogunniyi AO, Gonzalez C, Pride MW, Gierahn TM, Liberator PA, Jansen KU, Love JC.

PLoS One. 2017 Sep 14;12(9):e0183738. doi: 10.1371/journal.pone.0183738. eCollection 2017.

9.

Multiplex Urinary Antigen Detection for 13 Streptococcus pneumoniae Serotypes Improves Diagnosis of Pneumococcal Pneumonia in South African HIV-Infected Adults.

Albrich WC, Pride MW, Madhi SA, Callahan J, Adrian PV, French R, van Niekerk N, Sebastian S, Souza V, Telles JN, Paranhos-Baccalà G, Jansen KU, Klugman KP.

J Clin Microbiol. 2016 Dec 28;55(1):302-312. doi: 10.1128/JCM.01573-16. Print 2017 Jan.

10.

A phase 1, placebo-controlled, randomized study of the safety, tolerability, and immunogenicity of a Clostridium difficile vaccine administered with or without aluminum hydroxide in healthy adults.

Sheldon E, Kitchin N, Peng Y, Eiden J, Gruber W, Johnson E, Jansen KU, Pride MW, Pedneault L.

Vaccine. 2016 Apr 19;34(18):2082-91. doi: 10.1016/j.vaccine.2016.03.010. Epub 2016 Mar 15.

PMID:
26993331
11.

Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.

Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, van Werkhoven CH, van Deursen AM, Sanders EA, Verheij TJ, Patton M, McDonough A, Moradoghli-Haftvani A, Smith H, Mellelieu T, Pride MW, Crowther G, Schmoele-Thoma B, Scott DA, Jansen KU, Lobatto R, Oosterman B, Visser N, Caspers E, Smorenburg A, Emini EA, Gruber WC, Grobbee DE.

N Engl J Med. 2015 Mar 19;372(12):1114-25. doi: 10.1056/NEJMoa1408544.

12.

Predicting pneumococcal community-acquired pneumonia in the emergency department: evaluation of clinical parameters.

Huijts SM, Boersma WG, Grobbee DE, Gruber WC, Jansen KU, Kluytmans JA, Kuipers BA, Palmen F, Pride MW, Webber C, Bonten MJ; CAP Diagnostics investigators.

Clin Microbiol Infect. 2014 Dec;20(12):1316-22. doi: 10.1111/1469-0691.12740. Epub 2014 Dec 12.

13.

Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged ≥50 years with community-acquired pneumonia.

Sherwin RL, Gray S, Alexander R, McGovern PC, Graepel J, Pride MW, Purdy J, Paradiso P, File TM Jr.

J Infect Dis. 2013 Dec 1;208(11):1813-20. doi: 10.1093/infdis/jit506. Epub 2013 Oct 2.

PMID:
24092845
14.

Diagnostic accuracy of a serotype-specific antigen test in community-acquired pneumonia.

Huijts SM, Pride MW, Vos JM, Jansen KU, Webber C, Gruber W, Boersma WG, Snijders D, Kluytmans JA, van der Lee I, Kuipers BA, van der Ende A, Bonten MJ.

Eur Respir J. 2013 Nov;42(5):1283-90. doi: 10.1183/09031936.00137412. Epub 2013 Feb 8.

15.

Antibody responses to routine pediatric vaccines administered with 13-valent pneumococcal conjugate vaccine.

Bryant KA, Gurtman A, Girgenti D, Reisinger K, Johnson A, Pride MW, Patterson S, Devlin C, Gruber WC, Emini EA, Scott DA.

Pediatr Infect Dis J. 2013 Apr;32(4):383-8. doi: 10.1097/INF.0b013e318279e9a9.

PMID:
23104129
16.

Validation of an immunodiagnostic assay for detection of 13 Streptococcus pneumoniae serotype-specific polysaccharides in human urine.

Pride MW, Huijts SM, Wu K, Souza V, Passador S, Tinder C, Song E, Elfassy A, McNeil L, Menton R, French R, Callahan J, Webber C, Gruber WC, Bonten MJ, Jansen KU.

Clin Vaccine Immunol. 2012 Aug;19(8):1131-41. doi: 10.1128/CVI.00064-12. Epub 2012 Jun 6.

17.

Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease.

Jiang HQ, Hoiseth SK, Harris SL, McNeil LK, Zhu D, Tan C, Scott AA, Alexander K, Mason K, Miller L, DaSilva I, Mack M, Zhao XJ, Pride MW, Andrew L, Murphy E, Hagen M, French R, Arora A, Jones TR, Jansen KU, Zlotnick GW, Anderson AS.

Vaccine. 2010 Aug 23;28(37):6086-93. doi: 10.1016/j.vaccine.2010.06.083. Epub 2010 Jul 7.

PMID:
20619376
18.

Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide.

McNeil LK, Murphy E, Zhao XJ, Guttmann S, Harris SL, Scott AA, Tan C, Mack M, DaSilva I, Alexander K, Mason K, Jiang HQ, Zhu D, Mininni TL, Zlotnick GW, Hoiseth SK, Jones TR, Pride MW, Jansen KU, Anderson AS.

Vaccine. 2009 May 26;27(25-26):3417-21. doi: 10.1016/j.vaccine.2009.01.075. Epub 2009 Feb 5.

PMID:
19200847
19.

Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children.

Forrest BD, Pride MW, Dunning AJ, Capeding MR, Chotpitayasunondh T, Tam JS, Rappaport R, Eldridge JH, Gruber WC.

Clin Vaccine Immunol. 2008 Jul;15(7):1042-53. doi: 10.1128/CVI.00397-07. Epub 2008 Apr 30.

20.

Epitope mapping of full-length glycoprotein D from HSV-2 reveals a novel CD4+ CTL epitope located at the transmembrane-cytoplasmic junction.

Cooper D, Mester JC, Guo M, Nasar F, Souza V, Dispoto S, Sidhu M, Hagen M, Eldridge JH, Natuk RJ, Pride MW.

Cell Immunol. 2006 Feb;239(2):113-20. Epub 2006 Jun 9.

PMID:
16762332
21.

Interleukin-12 redirects murine immune responses to soluble or aluminum phosphate adsorbed HSV-2 glycoprotein D towards Th1 and CD4+ CTL responses.

Cooper D, Pride MW, Guo M, Cutler M, Mester JC, Nasar F, She J, Souza V, York L, Mishkin E, Eldridge J, Natuk RJ.

Vaccine. 2004 Nov 25;23(2):236-46.

PMID:
15531043
22.

Suppression of antigen-specific lymphocyte activation in modeled microgravity.

Cooper D, Pride MW, Brown EL, Risin D, Pellis NR.

In Vitro Cell Dev Biol Anim. 2001 Feb;37(2):63-5.

PMID:
11332738
23.
24.

Enhancement of cell-mediated immunity in melanoma patients immunized with murine anti-idiotypic monoclonal antibodies (MELIMMUNE) that mimic the high molecular weight proteoglycan antigen.

Pride MW, Shuey S, Grillo-Lopez A, Braslawsky G, Ross M, Legha SS, Eton O, Buzaid A, Ioannides C, Murray JL.

Clin Cancer Res. 1998 Oct;4(10):2363-70.

25.

Immunologic response to the dual murine anti-Id vaccine Melimmune-1 and Melimmune-2 in patients with high-risk melanoma without evidence of systemic disease.

Saleh MN, Lalisan DY Jr, Pride MW, Solinger A, Mayo MS, LoBuglio AF, Murray JL.

J Immunother. 1998 Sep;21(5):379-88.

PMID:
9789200
26.
27.

Origin and characteristics of ultraviolet-B radiation-induced suppressor T lymphocytes.

Shreedhar VK, Pride MW, Sun Y, Kripke ML, Strickland FM.

J Immunol. 1998 Aug 1;161(3):1327-35.

28.

Specific Th1 cell lines that confer protective immunity against experimental Borrelia burgdorferi infection in mice.

Pride MW, Brown EL, Stephens LC, Killion JJ, Norris SJ, Kripke ML.

J Leukoc Biol. 1998 May;63(5):542-9.

PMID:
9581797
29.

Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma.

Eton O, Kharkevitch DD, Gianan MA, Ross MI, Itoh K, Pride MW, Donawho C, Buzaid AC, Mansfield PF, Lee JE, Legha SS, Plager C, Papadopoulos NE, Bedikian AY, Benjamin RS, Balch CM.

Clin Cancer Res. 1998 Mar;4(3):619-27.

30.
32.

Molecular mimicry of hepatitis B surface antigen by an anti-idiotype-derived synthetic peptide.

Pride MW, Shi H, Anchin JM, Linthicum DS, LoVerde PT, Thakur A, Thanavala Y.

Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):11900-4.

33.
34.
36.

Supplemental Content

Loading ...
Support Center